According to the actual situation, this study will conduct a subgroup analysis of the heterogeneous outcome indicators in accordance with the use of nicorandil, the dosage, the treatment course of the drug, the age and gender of the patient to reduce the heterogeneity in the results and increase the stability of the results.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.